The unregulated hemp-derived cannabinoid marketplace has exploded since the 2018 Farm Bill descheduled hemp. The FDA has asked Congress to help with a “new regulatory pathway.”
Norman Birenbaum spoke about the FDA’s cannabis-related efforts during a discussion on Thursday hosted by the Council for Federal Cannabis Regulation.
Now that Congress will play a bigger role in the future of the CBD industry, will more companies try to sway the outcome?
The cannabis industry has long-awaited rules from the FDA to guide the CBD industry. Now, it’s up to Congress.
The 2018 Farm Bill legalized hemp, and, by extension, hemp-derived CBD, but the Food and Drug Administration has not yet released rules to guide the growing industry.
The Food and Drug Administration has said for years that it is working on rules for cannabinoid-containing products. But it has also said that crucial research and data are lacking.
A policy coordinator with the FDA’s Cannabis Product Committee spoke about CBD during a Food and Drug Law Institute event focused on cannabis.
The Food and Drug Administration has been on a march to collect cannabinoid-related data. The “Cannabis-Derived Products Data Acceleration Plan” released this month is its most robust effort.
Epidiolex strikes again: the FDA-approved CBD-based pharmaceutical is complicating other uses of CBD.
CSU Pueblo hosted a pharmacist at Greenwich Biosciences to talk about the company’s path with Epidiolex, a CBD-based medicine extracted from cannabis plants.
The group, which includes Coca-Cola and Kellogg’s as members, says its membership is “CBD curious” but that the lack of federal regulation is keeping major brands at bay.
“I’m getting very hopeful that we're headed down the road to seeing some hemp-derived ingredients approved for use in animal food,” said the FDA’s Deputy Director in the Division of Animal Feeds.
The FDA, which has been crafting rules for CBD products since 2019, says it is seeking partnerships, from academia to government and the cannabis industry, to “develop the foundation for more robust CBD data collection.”
The Food and Drug Law Institute is hosting officials from several federal agencies this week to discuss cannabis policies.
One company is focused on the future of CBD in supplements. The other, on its future in pharmaceuticals.
During a recent webinar, the FDA detailed how its Drug Master Files process could speed up research, while keeping proprietary information secret.